Cyclic peptides and aids vaccines

Details Cyclic peptides and aids vaccines Cyclic peptides and aids vaccines

2005-09-13

2005-09-13

Housel, James (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C514S002600, C514S009100, C514S011400, C930S010000, C930S020000, C930S220000, C930S270000, C530S350000

Reexamination Certificate

active

06943233

ABSTRACT:
Cyclic peptides which comprise, as a constituent chain or chains thereof, one or two amino acid sequences selected from the amino acid sequence Asn-Val-Ser-Glu-Ala-Asp-Asp-Arg-Tyr-Ile and the amino acid sequence Arg-Ser-Gln-Lys-Glu-Gly-Leu-His-Tyr-Thr, and AIDS vaccines containing at least one of the cyclic peptides as an active ingredient. From the in vivo absorption and antibody expression viewpoint, a substituent group is preferably bound to at least one active group selected from among the carboxyl, amino and hydroxyl groups contained in the cyclic peptides. The cyclic peptides can neutralize the second receptors which the HIV-1 virus utiliizes in the infection of humans therewith.

REFERENCES:
patent: 5229490 (1993-07-01), Tam
patent: WO9745543 (1997-04-01), None
patent: WO97/32019 (1997-09-01), None
patent: WO97/47318 (1997-12-01), None
patent: WO97/47319 (1997-12-01), None
patent: 00/47609 (2000-08-01), None
Bende. et al. Update: Search for an AIDS vaccine. AIDS Read, 10(9), 2000, pp. 526-537.
Beyrer. The HIV/AIDS vaccine research effort: An update. The Johns Hopkins University AIDS Service, The Hopkins HIV Report, vol. 15 (1), Jan. 2003, pp. 1-16.
Feinberg et al. AIDS vaccine models: challenging challenge viruses. Nature Medicine, vol. 8 (3), Mar. 2002, pp. 207-210.
Misumi et al. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression. Journal of Biological Chemistry, vol. 278, No. 34, 2003, pp. 32335-32343.
Klausner et al. The need for a global HIV vaccine enterprise. Science, vol. 300, Jun. 2003, pp. 2036-2039.
Desrosiers. Prospects for an AIDS vaccine. Nature Medicine, vol. 10(3), Mar. 2004, pp. 221-223.
Nabel. Challenges and opportunities of development of an AIDS vaccine. Nature, vol. 410, Apr. 2001, pp. 1002-1007.
Lee. Chapter 32 AIDS Vaccines: 32.1 Acquired immunodeficiency disease vaccines: design and development. AIDS: Biology, Diagosis, Treatment, and Prevention, fourth edition, edited by DeVitat, Jr. et al., Lippincott-Raven, 1997, pp. 605-616.
Dorang et al. Identification of CXCR4 Domains that Support Coreceptor and Chemokine Receptor Functions. Journal of Virology. 1999. vol. 73, No. 4, 2752-2761.
Reeves et al. The Second Extracellular Loop of CXCR4 is Involved in C04-Independent Entry of Human Immunodeficiency Virus Type 2. Journal of General Virology. 1998, vol. 79, 1793-1799.
Olson et al. Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, ge 120 Binding and CC-Chemokine Activity by monoclonal Antibodies to CCAS. Journal of Virology, 1999, vol. 73, No. 5, 4145-4155.
Dictionary of Immunology, Tokyo Kagaku Gojin K.K. 1993, p. 319.
HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor. Yu Feng et al. Science, vol. 272, pp 872-877. May 10, 1996.
Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection. Rong Liu et al. Cell, vol. 86, pp. 367-377. Aug. 9, 1996.
Ido et al, Dec. 12-13, 1998, 15th Meeting of the Japan Pharmacology Academy, Chemical Synthesis of a cyclo-oligo peptide and its biological activity.

Affiliated with

Also associated with

Rating

Cyclic peptides and aids vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic peptides and aids vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptides and aids vaccines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3374675